Rune Labs

About

Rune Labs is a software and data analytics company for precision neurology, founded in October 2018 in San Francisco ¹. The company develops clinical brain data software that integrates electrophysiology, brain imaging, device data, wearables, and clinical information to advance treatment for neurodegenerative and psychiatric diseases including Parkinson’s disease, multiple sclerosis, and depression ². Co-founded by CEO Brian Pepin and CTO Miro Kotzev, the company is headquartered near the main neurosurgery campus for UCSF ¹.

Rune Labs’ primary product is StrivePD, a care delivery ecosystem for Parkinson’s disease that enables patients and clinicians to better manage the condition through curated dashboards summarizing patient data sources ³. In June 2022, StrivePD received FDA 510(k) clearance to collect patient symptom data via Apple Watch, leveraging Apple’s Movement Disorder API to measure tremors and dyskinetic symptoms ⁴. The company also partners with Medtronic, integrating with its Percept PC Deep Brain Stimulation device ⁴. In March 2023, Rune Labs launched StriveStudy, a clinical trial platform ¹.

As of early 2026, Amy Gordon Franzen serves as CEO, with Brian Pepin serving as President of Biopharma and Platform ¹.

Funding History

Additional investors listed on the company website include Village Global and City Light Capital ¹. Other known investors across rounds include Samsung NEXT Ventures, 468 Capital, UCSF Rosenman Institute, and Daybreak Partners ⁷.

Total raised: approximately $57M across all rounds ⁷.

What Investors Say

Justin Butler, Partner at Eclipse Ventures, on the Series A: “Rune Labs’ software platform aggregates brain data into an integrated environment, enabling precision neuromedicine.” ²

David J. Kim, DigiTx Partners, on the Seed round: “The technology Rune Labs is developing with neurologic and biometric data will optimize clinical care for many individuals with debilitating neurological and mental health conditions.” ⁵

Dr. Jordi Parramon, CEO of Nexus NeuroTech Ventures, on the Strategic round: “The future of precision medicine for brain diseases will start with innovative technologies that provide personalized, longitudinal insights.” ⁶

What Founders Say

Brian Pepin, Founder, on the Series A: “This financing will enable us to expand the number of patients, clinicians, and researchers using our platform to inform precision therapy development.” ²

Brian Pepin, on the Seed round: “Strong financial backing from credible partners and world-class academic collaborators continues to position us to help better understand the brain.” ⁵

Brian Pepin, on the FDA clearance: “This clearance is a major step towards building a similar paradigm in neurology” as seen in oncology’s use of real-world data. ⁴

Brian Pepin, on the Strategic round, stated the company will use the funds to push adoption of its technology among health plans that can use it to manage care for their members with Parkinson’s disease ⁸.

Sources